Alembic Pharma Shares Soar 14%, Gets USFDA Nod For Key Cancer Drug

Mumbai: Shares of Alembic Pharmaceuticals surged 13.61 percent on Monday after a major regulatory approval. The stock hit a high of Rs 1,104.10 during the day.

The reason for this rise? Alembic got final approval from the US Food and Drug Administration (USFDA) for its cancer drug — Doxorubicin Hydrochloride Liposome Injection.

About the Approved Drug

This injection is used to treat:

- Ovarian Cancer

- AIDS-related Kaposi’s Sarcoma

- Multiple Myeloma

The drug will be available in two strengths:

20 mg/10 mL (2 mg/mL)

50 mg/25 mL (2 mg/mL)

According to IQVIA, the US market size for this medicine is about $29 million for the 12 months ending March 2025.

Market Outlook 24th Jun 2025: Technical Call Of The Day & Top 5 Stocks In Focus For 24th June 2025

Alembic’s Growing USFDA Approvals

With this approval, Alembic now has a total of 224 USFDA-approved drugs:

- 201 final approvals

- 23 tentative approvals

This strengthens the company’s presence in the regulated US market.

Stock Technicals and Valuation

Technically, the stock is in a strong zone and trades above all major moving averages (5-day to 200-day SMAs).

Its 14-day RSI is 74.41, which means the stock is now in an overbought zone.

From a valuation point:

P/E Ratio: 34.36

P/B Ratio: 4.30

EPS: Rs 32.03

Return on Equity (RoE): 12.51 percent

Beta (1-year): 0.46 (low volatility)

Strong Promoter Holding

As of March 2025, promoters hold 69.67 percent stake in Alembic Pharmaceuticals. This indicates strong promoter confidence.